First big depression advance since Prozac nears FDA approval
February 14, 2019

From Bloomberg:

The U.S. Food and Drug Administration is on the brink of approving a breakthrough drug that could upend the way severe depression is treated.

Johnson & Johnson's esketamine, a close chemical cousin of the anesthetic ketamine, cleared a major hurdle on Tuesday when a panel of outside experts recommended that the FDA approve the treatment. The fast-acting antidepressant, administered via a nasal spray, is being tested in major depressive disorder and suicidal thinking. If approved, it would be the first major therapeutic advance for depression since the introduction of Prozac in 1987.

Prozac and other currently available antidepressants take weeks to work and don't help all patients, so esketamine could mark a significant shift in depression therapy.

Continue reading at Bloomberg...

You may also like

Got a minute? Global attention span is narrowing, study reveals

"Research combed from everything from movie tickets to social media finds more to focus on but less time to do so."

Americans are delaying health care until tax refunds arrive

"Out-of-pocket medical spending jumps once the money hits people’s bank accounts."

Drug tests show marijuana use at 14-year high among workers

"More than 2% of U.S. employees test positive for drug as legalization expands."